NASDAQ:APLT Applied Therapeutics (APLT) Stock Price, News & Analysis $0.10 0.00 (0.00%) As of 07/31/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Applied Therapeutics Stock (NASDAQ:APLT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Applied Therapeutics alerts:Sign Up Key Stats Today's Range$0.10▼$0.1050-Day Range$0.10▼$0.1052-Week Range$0.09▼$1.50VolumeN/AAverage Volume7.28 million shsMarket Capitalization$15.86 millionP/E RatioN/ADividend YieldN/APrice Target$1.00Consensus RatingReduce Company Overview Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapies for genetically defined diseases. Its research strategy centers on structure-based drug design and proprietary screening technologies aimed at correcting underlying metabolic dysfunction in disorders characterized by enzyme deficiencies and toxic metabolite accumulation. The company’s lead investigational candidate, AT-007, is an aldose reductase inhibitor engineered to cross the blood–brain barrier and is currently in clinical development for classic galactosemia. In addition to AT-007, Applied Therapeutics is advancing multiple programs targeting rare neurological and endocrine disorders, leveraging its platform to identify and optimize compounds that address high unmet medical needs in orphan and genetically defined patient populations. Founded and headquartered in New York City, Applied Therapeutics has established collaborative partnerships with academic research institutions and contract research organizations throughout North America and Europe to support its preclinical and clinical operations. The company is guided by a leadership team with extensive experience in drug discovery, clinical development and regulatory affairs, positioning Applied Therapeutics to advance its pipeline toward key clinical milestones and potential regulatory approval.AI Generated. May Contain Errors. Read More Applied Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreAPLT MarketRank™: Applied Therapeutics scored higher than 30% of companies evaluated by MarketBeat, and ranked 766th out of 894 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.8 / 5Analyst RatingReduce Consensus RatingApplied Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialApplied Therapeutics has a consensus price target of $1.00, representing about 870.9% upside from its current price of $0.10.Amount of Analyst CoverageApplied Therapeutics has received no research coverage in the past 90 days.Read more about Applied Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Applied Therapeutics are expected to grow in the coming year, from ($0.65) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Applied Therapeutics is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Applied Therapeutics is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApplied Therapeutics has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for APLT. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldApplied Therapeutics does not currently pay a dividend.Dividend GrowthApplied Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for APLT on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Applied Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders1.60% of the stock of Applied Therapeutics is held by insiders.Percentage Held by Institutions98.31% of the stock of Applied Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Applied Therapeutics' insider trading history. Receive APLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APLT Stock News HeadlinesApplied Therapeutics Stock Short Interest Report | NASDAQ:APLT | BenzingaJuly 12, 2026 | benzinga.comCycle Pharmaceuticals Completes Acquisition of Applied TherapeuticsFebruary 3, 2026 | businesswire.comALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's latest AI patent as the catalyst behind their next major call. They say a market pattern with a 100% historical track record is converging with this new breakthrough by end of month. The last time conditions aligned like this, investors had the chance to turn $10,000 into as much as $350,000 in roughly 12 months. Brown and Chaikin have released the full details for investors who want to get ahead of it.August 2 at 1:00 AM | Brownstone Research (Ad)Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender OfferJanuary 30, 2026 | businesswire.comApplied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration ExtensionJanuary 29, 2026 | globenewswire.comCycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender OfferJanuary 29, 2026 | businesswire.comCycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender OfferJanuary 28, 2026 | businesswire.comApplied Therapeutics (APLT) price target decreased by 85.00% to 0.26December 22, 2025 | msn.comSee More Headlines APLT Stock Analysis - Frequently Asked Questions How have APLT shares performed this year? Applied Therapeutics' stock was trading at $0.10 at the beginning of the year. Since then, APLT stock has increased by 3.0% and is now trading at $0.1030. How were Applied Therapeutics' earnings last quarter? Applied Therapeutics Inc. (NASDAQ:APLT) posted its quarterly earnings data on Thursday, November, 13th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.02. The company earned $1 million during the quarter, compared to analyst estimates of $0.25 million. When did Applied Therapeutics IPO? Applied Therapeutics (APLT) raised $60 million in an initial public offering (IPO) on the week of May 13th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank served as the underwriters for the IPO and Baird was co-manager. How do I buy shares of Applied Therapeutics? Shares of APLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Applied Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Applied Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), Advanced Micro Devices (AMD) and ServiceNow (NOW). Company Calendar Last Earnings11/13/2025Today8/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 APLT's financial health is in the Red zone, according to TradeSmith. APLT has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:APLT CIK1697532 Webwww.appliedtherapeutics.com Phone(212) 220-9226FaxN/AEmployees30Year Founded2017Price Target and Rating Average Price Target for Applied Therapeutics$1.00 High Price Target$1.00 Low Price Target$1.00 Potential Upside/Downside+870.9%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$105.62 million Net MarginsN/A Pretax Margin-1,813.80% Return on Equity-340.84% Return on Assets-175.00% Debt Debt-to-Equity RatioN/A Current Ratio0.96 Quick Ratio0.96 Sales & Book Value Annual Sales$1 million Price / Sales15.86 Cash FlowN/A Price / Cash FlowN/A Book Value$0.49 per share Price / Book0.21Miscellaneous Outstanding Shares153,958,000Free Float151,495,000Market Cap$15.86 million OptionableOptionable Beta2.08 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:APLT) was last updated on 8/2/2026 by MarketBeat.com Staff. From Our PartnersAI is not overTesla and Alphabet just tumbled, and many investors concluded AI is over. It isn't - the easy AI trade may be....The Oxford Club | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | SponsoredNvidia's CEO says this small device is critical for AI growthA tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it esse...Brownstone Research | SponsoredThe dollar just brokeBloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...Porter & Company | SponsoredDid you forget to grab this?Most beginners stay stuck on the sidelines for years because no one shows them the simple steps between being ...Profits Run | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Applied Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Applied Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
